{"id":"W3174706170","doi":"10.1016/j.ejca.2021.05.025","title":"Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Saskatchewan Cancer Agency; BC Cancer Agency; Jewish General Hospital","funders":"Daiichi Sankyo Europe; EMD Serono; Genentech; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; MacroGenics; Silverback Therapeutics; Pfizer; NuCana; Regeneron Pharmaceuticals; Mylan; Unum Therapeutics; Helsinn Therapeutics; Amgen; Radius Health; Syndax Pharmaceuticals; Clovis Oncology; Teva Pharmaceutical Industries; Helsinn; Les Laboratories Pierre Fabre; Taiho Pharmaceutical; Eli Lilly and Company; AstraZeneca; Foundation Medicine; National Cancer Research Institute; Genomic Health; Mersana Therapeutics; Karyopharm Therapeutics; Puma Biotechnology","keywords":"Capecitabine; Trastuzumab; Metastatic breast cancer; Oncology; Medicine; Human Epidermal Growth Factor Receptor 2; Internal medicine; Placebo; Breast cancer; Cancer; Pathology; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003473749,0.0001986725,0.0008205675,0.0001540535,0.00003090976,0.000009766959,0.00007758368,0.00002023656,0.0016386],"category_scores_gemma":[0.0001135049,0.0001256899,0.00006501523,0.0003040228,0.00008082326,0.0001801807,0.00002284487,0.0001831525,4.93346e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002186303,"about_ca_system_score_gemma":0.0006155957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007751114,"about_ca_topic_score_gemma":0.00130148,"domain_scores_codex":[0.9976304,0.0007208457,0.0008667036,0.0002075398,0.0003933081,0.0001811619],"domain_scores_gemma":[0.9975891,0.0001699478,0.0008597151,0.0001167445,0.001048291,0.0002162396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3272972,0.001961232,0.6492789,0.0003124668,0.001747244,0.00007785146,0.00505809,0.00005379111,0.006518989,0.000005456307,0.001202184,0.006486518],"study_design_scores_gemma":[0.1007738,0.006370574,0.8866827,0.0005832585,0.0004933666,0.000009834362,0.0002674148,0.000001860139,0.004569008,0.000001296708,0.0001172091,0.0001296816],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996543,0.0004736547,0.00001979051,0.001527564,0.00007993148,0.0007173167,0.000417714,0.000004400521,0.0002166408],"genre_scores_gemma":[0.9983582,0.0001215894,0.0005315975,0.000283721,0.0001540877,0.00002342598,0.00003627489,0.00003651832,0.0004546027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2374038,"threshold_uncertainty_score":0.999274,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05052952878100639,"score_gpt":0.3440817760243052,"score_spread":0.2935522472432988,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}